Luz Hammershaimb

2.4k total citations · 1 hit paper
19 papers, 1.9k citations indexed

About

Luz Hammershaimb is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Luz Hammershaimb has authored 19 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Luz Hammershaimb's work include Colorectal Cancer Treatments and Studies (6 papers), T-cell and Retrovirus Studies (4 papers) and Cell Adhesion Molecules Research (4 papers). Luz Hammershaimb is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), T-cell and Retrovirus Studies (4 papers) and Cell Adhesion Molecules Research (4 papers). Luz Hammershaimb collaborates with scholars based in United States, France and Germany. Luz Hammershaimb's co-authors include F. Gamza, Frank V. Fossella, Jeffrey Crawford, Vincent A. Miller, Daniel D. Karp, Jin Soo Lee, Everett E. Vokes, Mark G. Kris, Yong Kim and Leonard Kalman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Luz Hammershaimb

19 papers receiving 1.8k citations

Hit Papers

Randomized Phase III Trial of Docetaxel Versus Vinorelbin... 2000 2026 2008 2017 2000 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
    2000 1.1k citations Frank V. Fossella, Russell F. DeVore et al. Journal of Clinical Oncology profile →

Peers

Luz Hammershaimb
Shuchi S. Pandya United States
H Sawada Japan
Colin Marsh United Kingdom
K. Pittman Australia
Hideoki Yokouchi Japan
Christopher J. Lafargue United States
Eckart Laack Germany
Sergi Benavente Spain
Rüdiger Hein Germany
Wolf‐Dietrich Beecken Germany
Shuchi S. Pandya United States
Luz Hammershaimb
Citations per year, relative to Luz Hammershaimb Luz Hammershaimb (= 1×) peers Shuchi S. Pandya

Countries citing papers authored by Luz Hammershaimb

Since Specialization
Citations

This map shows the geographic impact of Luz Hammershaimb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luz Hammershaimb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luz Hammershaimb more than expected).

Fields of papers citing papers by Luz Hammershaimb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luz Hammershaimb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luz Hammershaimb. The network helps show where Luz Hammershaimb may publish in the future.

Co-authorship network of co-authors of Luz Hammershaimb

This figure shows the co-authorship network connecting the top 25 collaborators of Luz Hammershaimb. A scholar is included among the top collaborators of Luz Hammershaimb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luz Hammershaimb. Luz Hammershaimb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Hersey, Peter, Jeffrey A. Sosman, Steven O’Day, et al.. (2010). A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma. Cancer. 116(6). 1526–1534. 150 indexed citations
2.
Moschos, Stergios J., Cindy Sander, Wenjun Wang, et al.. (2010). Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma. Journal of Immunotherapy. 33(3). 316–325. 20 indexed citations
3.
O’Mahony, Deirdre, John C. Morris, Maryalice Stetler‐Stevenson, et al.. (2009). EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies. Clinical Cancer Research. 15(7). 2514–2522. 35 indexed citations
4.
Delbaldo, Catherine, Éric Raymond, Karina Vera, et al.. (2007). Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors. Investigational New Drugs. 26(1). 35–43. 82 indexed citations
5.
O’Mahony, Deirdre, John C. Morris, Maryalice Stetler‐Stevenson, et al.. (2007). EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.. Blood. 110(11). 3565–3565. 7 indexed citations
6.
Janik, John E., John C. Morris, Wendy Gao, et al.. (2005). Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease. Journal of Immunotherapy. 28(6). 644–644. 10 indexed citations
7.
McNeel, Douglas G., Jens C. Eickhoff, Fred T. Lee, et al.. (2005). Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion. Clinical Cancer Research. 11(21). 7851–7860. 121 indexed citations
8.
Janik, John E., John C. Morris, M Stetler-Stevenson, et al.. (2005). Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. Journal of Clinical Oncology. 23(16_suppl). 2533–2533. 4 indexed citations
9.
O’Mahony, Deirdre, John C. Morris, Wendy Gao, et al.. (2005). Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.. Blood. 106(11). 3353–3353. 20 indexed citations
10.
Bruno, René, Robert Olivares, J. Bérille, et al.. (2003). Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.. PubMed. 9(3). 1077–82. 68 indexed citations
11.
12.
Punt, Cornelis J.A., H.J. Keizer, J. Douma, et al.. (2002). Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Annals of Oncology. 13(1). 81–86. 21 indexed citations
13.
Blanke, Charles D., Jeffrey Shultz, James D. Cox, et al.. (2002). A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Annals of Oncology. 13(1). 87–91. 24 indexed citations
14.
Buentzel, Jens, Alain Monnier, J. Ammon, et al.. (2001). Phase III randomized double blind placebo controlled trial of carboplatin and radiation therapy ± amifostine in patients with head and neck cancer. International Journal of Radiation Oncology*Biology*Physics. 51(3). 85–85. 3 indexed citations
15.
16.
Fossella, Frank V., Russell F. DeVore, Jeffrey Crawford, et al.. (2000). Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens. Journal of Clinical Oncology. 18(12). 2354–2362. 1124 indexed citations breakdown →
17.
Hughes, Kevin S., Carl Pinsky, Nicholas J. Petrelli, et al.. (1997). Use of Carcinoembryonic Antigen Radioimmunodetection and Computed Tomography for Predicting the Resectability of Recurrent Colorectal Cancer. Annals of Surgery. 226(5). 621–631. 41 indexed citations
18.
19.
Pinsky, Carl, Luz Hammershaimb, Nicholas J. Petrelli, et al.. (1994). CLINICAL UTILITY OF IMAGING WITH 99=TC-LABELED IMMU-4 Fab' FRAGMENT IN PATIENTS(pts) WITH CANCER OF THE COLON OR RECTUM. Journal of Immunotherapy. 16(2). 153–153. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shuchi S. Pandya Breakdown of academic impact, for papers by H Sawada Breakdown of academic impact, for papers by Colin Marsh Breakdown of academic impact, for papers by K. Pittman Breakdown of academic impact, for papers by Hideoki Yokouchi Breakdown of academic impact, for papers by Christopher J. Lafargue Breakdown of academic impact, for papers by Eckart Laack Breakdown of academic impact, for papers by Sergi Benavente Breakdown of academic impact, for papers by Rüdiger Hein Breakdown of academic impact, for papers by Wolf‐Dietrich Beecken
Rankless by CCL
2026